Over-expression of specific Interleukins drive serious inflammatory diseases. Interleukins IL17A and IL17F plays a major role in inflammatory diseases, including the skin diseases psoriasis and hidradenitis suppurativa (HS), and joint diseases such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS). These are long-term conditions that severely impact patients’ lives. Therapeutical solutions that elevate treatment goals are critical to address important unmet needs.
Jorge Santos da Silva
Founder & Chief Executive Officer
We go beyond by bringing unrivalled expertise and experience to innovate the way new treatments are developed for inflammatory diseases.
We apply stellar science, sponsoring innovative research work and clinical trials globally, to target inflammatory diseases with a major unmet need where Sonelokimab has the potential to transform patient outcomes.
We are unlocking the value of Sonelokimab with our ambitious Phase 3 program across lead indications for hidradenitis suppurativa and psoriatic arthritis.
We go beyond by bringing unrivalled expertise and experience to innovate the way new treatments are developed for inflammatory diseases.
We apply stellar science, sponsoring innovative research work and clinical trials globally, to target inflammatory diseases with a major unmet need where Sonelokimab has the potential to transform patient outcomes.
We are unlocking the value of Sonelokimab with our ambitious Phase 2 program across lead indications for hidradenitis suppurativa and psoriatic arthritis.
